Ipsen to showcase commitment to going beyond traditional outcome measures for patients living with renal cell carcinoma at ASCO GU 2021

10 abstracts to be presented showcasing promising data across multiple genitourinary cancers, including renal cell carcinoma (RCC) and prostate cancer1-11

Highlights include extended follow-up and health-related quality of life data from the pivotal CheckMate -9ER trial, further supporting superiority of Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) versus sunitinib in first-line advanced RCC1,2

Additionally, a comparative, retrospective real-world evidence study suggested consistent efficacy of Cabometyx® after treatment with checkpoint inhibitors (CPI) as well as a significantly higher response rate and a higher time to discontinuation versus other tyrosine kinase inhibitors (TKIs) in second-line metastatic RCC3

PARIS, FRANCE, 5 February 2021– Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from its growing oncology portfolio will be presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place virtually from 11-13 February 2021.11 A total of 10 abstracts spanning several genitourinary cancers including advanced RCC, and metastatic, castration-resistant prostate cancer (mCRPC), highlight the utility of Ipsen’s medicines and its commitment to advancing patient care.1-10

“The presentations showcased at ASCO GU exemplify Ipsen’s commitment to prioritize outcome measures which directly impact patients’ lives,” said Amauri Soares, Vice President, Medical Affairs Oncology, Ipsen. “New data from the Phase III CheckMate -9ER trial highlight how first-line treatment with the combination of cabozantinib and nivolumab has the potential to extend the lives of patients living with advanced RCC without having to compromise on quality of life compared with sunitinib. We’re looking forward to sharing these data with the medical community at ASCO GU and bringing this important treatment option to patients at the earliest opportunity.”

Highlights from key data on Ipsen medicines to be presented during the ASCO GU 2021 Symposium include:

Extended follow-up outcomes data from the CheckMate -9ER study including patients living with advanced RCC and sarcomatoid features (sRCC) – an aggressive histologic subtype associated with poor prognoses1
Patient reported outcomes of patients living with advanced RCC – additional analysis from the CheckMate -9ER study of the combination of Cabometyx® (cabozantinib) with Opdivo® (nivolumab) versus sunitinib2
A comparative, retrospective real-world evidence study suggesting Cabometyx® (cabozantinib) was associated with a significantly higher response rate versus other TKIs (axitinib, lenvatinib, pazopanib, sorafenib, sunitinib) in patients living with metastatic renal cell carcinoma (mRCC) following checkpoint inhibitor (CPI) treatment3
Findings from a study using machine learning to explore the potential synergistic effects of Cabometyx® (cabozantinib) and a programmed cell death protein 1 (PD1) inhibitor in mRCC4
Trial design of the Phase III randomized, open-label CONTACT-02 study of Cabometyx® (cabozantinib) plus Tecentriq® (atezolizumab) versus second novel hormone therapy (NHT) in patients living with mCRPC5

Follow Ipsen on Twitter via @IpsenGroup and keep up to date with ASCO GU Symposium news and updates by using the hashtag #GU21.

References

Motzer et al., ASCO-GU 2021. Nivolumab + cabozantinib (NIVO+CABO) vs sunitinib (SUN) as first-line therapy for advanced renal cell carcinoma (aRCC): extended follow-up and outcomes in the sarcomatoid subgroup of CheckMate -9ER.
Cella et al., ASCO-GU 2021. Patient-reported outcomes (PROs) of patients (pts) with advanced renal cell carcinoma (aRCC) treated with first-line (1L) nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN): the randomized phase 3 CheckMate -9ER trial.
Marteau et al., ASCO-GU 2021. Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with mRCC.
Costa et al., ASCO-GU 2021. Exploring the synergistic effects of cabozantinib (cabo) and a programmed cell death protein 1 (PD1) inhibitor in metastatic renal cell carcinoma (mRCC) with artificial intelligence (AI).
Agarwal et al., ASCO-GU 2021. A phase 3, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

Attachment

Ipsen-ASCO-GU-2021-5-February-2021